U.S. License Holder:
Janssen Biotech
Date of License:
July-13-2017
Last Update:
Dec-15-2024
FDA-Approved Indications
TREMFYA (guselkumab) is an interleukin-23 blocker indicated for the treatment of adult patients with:
Moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy;
Active psoriatic arthritis;
Moderately to severely active ulcerative colitis